Metabolic & Cardiometabolic
GLP-1 receptor agonists decreases major adverse cardiovascular events
In plain terms: Do GLP-1 weight-loss/diabetes drugs actually lower the risk of heart attacks and strokes?
Strong support Metabolic & Cardiometabolic
Part of: 💊 GLP-1 Drugs
RefutedContestedStrong support
consensus score 0.90
Yes — across multiple large randomized trials and meta-analyses they cut major cardiovascular events by roughly 12-20%, in people with diabetes and (per SELECT) in obesity without diabetes.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
20 support 0 contradict 0 tested null 2 mixed · 22 sources, 19 independent groups · 4 superseded — pooled inside a review, counted once
The evidence (26)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Parekh RS et al 2026 · study_type: observational | observational | supports | low | Systematic review (PRISMA, 8/110 records included) on thromboembolic risk with GLP-1RAs in high-risk populations; narrative synthesis cites CVOT-derived MACE hazard ratios of 0.80 (0.72-0.90) and 0.74 (0.58-0.95) as established background r |
| Khera 2024 · J Am Coll Cardiol | observational | mixed | moderate | LEGEND-T2DM federated real-world analysis: GLP-1RA broadly favorable for CV outcomes vs other 2nd-line agents; non-randomized. |
| Abdul Nabi H et al 2026 · study_type: observational | observational | supports | moderate | Retrospective multicenter cohort (162,126 TAA patients, Mayo Clinic), propensity-matched. GLP-1RA therapy associated with higher MACE-free survival (93.2% vs 89.3%; HR 0.62, 95% CI 0.56-0.70) and overall survival (HR 0.32, 95% CI 0.27-0.38) |
| Amorim 2026 · Chronic Dis Transl Med | observational | supports | moderate | Review synthesizing CVOTs (LEADER/SUSTAIN-6/SELECT/REWIND) as consistent MACE reduction; mechanism via weight/lipids/inflammation. |
| Mahmoud AK et al 2026 · study_type: observational | observational | supports | moderate | Multicenter retrospective cohort, 3310 matched pairs with elevated Lp(a) and obesity/T2D. GLP-1RA use associated with lower all-cause mortality (HR 0.66, 95% CI 0.48-0.90) and reduced MACE (HR 0.68, 95% CI 0.60-0.76). |
| Kosako Yost KC et al 2026 · study_type: observational | observational | supports | low | Retrospective chart review, 457 liver/liver-kidney transplant patients with diabetes, 33 on GLP-1RA/SGLT2i. Combined group had lower 5-year post-transplant MACE (adjusted subdistribution HR 0.24, 95% CI 0.059-0.99). |
| Dai H et al 2026 · study_type: observational | observational | supports | moderate | Target trial emulation (OneFlorida+ EHR), 13,204 matched pairs with obesity + autoimmune disease. GLP-1RA use associated with lower stroke/TIA (HR 0.87), pulmonary embolism (HR 0.69), VTE (HR 0.83), and mortality (HR 0.56). |
| Sattar 2021 · Lancet Diabetes Endocrinol | meta-analysis | supports | high | Updated MA of 8 CVOTs: MACE HR 0.86 (14% reduction); all-cause mortality and kidney outcomes also reduced. |
| Raslan MA et al 2026 · study_type: observational | observational | supports | moderate | Retrospective cohort, 588 propensity-matched pairs with thoracic aortic aneurysm. GLP-1RA use associated with lower cardiovascular mortality (1.9% vs 5.5%; HR 0.30, 95% CI 0.13-0.70) and all-cause mortality (HR 0.31, 95% CI 0.19-0.50). |
| McGuire 2025 · N Engl J Med | RCT | supports | high | SOUL: oral semaglutide reduced MACE in high-risk T2D (HR 0.86, 95% CI 0.77-0.96); extends benefit to oral formulation. |
| Caruso P et al 2026 · study_type: meta-analysis | meta-analysis | supports | moderate | Systematic review and meta-analysis of 12 studies (2 RCTs, 10 cohorts), 418,282 participants with T2D+PAD. GLP-1RA associated with lower MACE (RR 0.76, 95% CI 0.63-0.90) alongside reduced limb events and mortality. |
| Ahmed A et al 2026 · Research Square | meta-analysis | supports | low | Network meta-analysis (93 studies, N>4,200,000) comparing zoster vaccine, SGLT2i, and GLP-1RA for MACE/dementia prevention in adults ≥50y. GLP-1RA arm: NMA-HR 0.86 (95% CrI 0.80-0.92) for MACE vs comparators. |
| Dhamelia P et al 2026 · study_type: observational | observational | supports | moderate | TriNetX retrospective cohort, 37,768 matched pairs with non-dialysis CKD. GLP-1RA use associated with lower MACE (HR 0.58, 95% CI 0.56-0.59), consistent even in non-diabetic/non-obese subgroups. |
| Gerstein 2019 · Lancet | RCT | supports | high | REWIND: dulaglutide reduced MACE in broad T2D pop (mostly primary prevention) HR 0.88 (95% CI 0.79-0.99). ↩ SUPERSEDED — pooled in the review above, counted once |
| Peter K et al 2026 · study_type: meta-analysis | meta-analysis | supports | high | Systematic review and meta-analysis of 11 randomized placebo-controlled CVOTs, 91,490 high-CV-risk participants, mean follow-up 2.7 years. GLP-1RA treatment significantly reduced MACE (HR 0.86, 95% CI 0.81-0.92) plus CV/all-cause mortality, |
| Kristensen 2019 · Lancet Diabetes Endocrinol | meta-analysis | supports | high | MA of 7 CVOTs (n=56,004): MACE HR 0.88 (12% reduction); CV death, stroke, MI, HF admission, kidney all lower. |
| Batista PG et al 2026 · study_type: meta-analysis | meta-analysis | mixed | moderate | Systematic review/meta-analysis, 7 studies, 37,393 T2D patients with prior MI (9556 on GLP-1RA). MACE HR 0.69 (95% CI 0.56-0.84) with standard model, but significance lost under HKSJ sensitivity adjustment (P=0.13) with substantial heteroge |
| Ritsinger 2026 · Diabetes Obes Metab | observational | supports | moderate | Swedish real-world SELECT-like obesity cohort: high baseline CV event rates support meaningful preventive potential of semaglutide. |
| Maggioni 2026 · Int J Cardiol | observational | supports | low | Eligibility analysis citing SELECT+SOUL as establishing MACE reduction; real-world cohorts differ from trials. |
| Montenegro-Avila A et al 2026 · study_type: meta-analysis | meta-analysis | supports | high | Systematic review/meta-analysis of 7 RCTs, 56,191 participants with T2D and established ASCVD. GLP-1RAs reduced MACE by 11% (HR 0.89, 95% CI 0.83-0.96), all-cause mortality by 11%, and HF hospitalization by 7%, all high-certainty evidence. |
| Marso 2016 · N Engl J Med | RCT | supports | high | SUSTAIN-6: semaglutide cut MACE in T2D (HR 0.74, 95% CI 0.58-0.95), driven by nonfatal stroke; pre-specified noninferiority trial. ↩ SUPERSEDED — pooled in the review above, counted once |
| Lincoff 2023 · N Engl J Med | RCT | supports | high | SELECT: in obesity w/o diabetes + CVD, semaglutide 2.4mg cut MACE 20% (HR 0.80, 95% CI 0.72-0.90) over ~40mo. ↩ SUPERSEDED — pooled in the review above, counted once |
| Chen JJ et al 2026 · study_type: observational | observational | supports | moderate | Propensity-matched retrospective cohort (TriNetX), 1688 matched pairs of dialysis patients with T2D. GLP-1RA users had lower MACE than DPP-4i users (HR 0.88, 95% CI 0.78-0.99), plus reduced mortality, MI, heart failure, and sepsis. |
| Badve 2025 · Lancet Diabetes Endocrinol | meta-analysis | supports | high | MA incl SELECT/FLOW: GLP-1RA reduce CV and kidney composite outcomes across diabetic and non-diabetic populations. |
| Marso 2016 · N Engl J Med | RCT | supports | high | LEADER: liraglutide reduced MACE in T2D w/ high CV risk (HR 0.87, 95% CI 0.78-0.97); CV death also lower. ↩ SUPERSEDED — pooled in the review above, counted once |
| Hasebe M et al 2026 · study_type: meta-analysis | meta-analysis | supports | high | Updated meta-analysis of RCTs including SOUL trial, 8 trials/70,822 participants with T2D or overweight/obesity. GLP-1RAs reduced MACE similarly across eGFR strata: HR 0.83 (95% CI 0.77-0.90) for eGFR≥60 and HR 0.83 (95% CI 0.74-0.93) for e |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.